Skip to main content
Clinical Trials/NCT05135520
NCT05135520
Unknown
Not Applicable

A Prospective Randomized Controlled Study of Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen (STTELS)

Seoul National University Bundang Hospital0 sites106 target enrollmentNovember 29, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Urologic Neoplasms
Sponsor
Seoul National University Bundang Hospital
Enrollment
106
Primary Endpoint
Patient and Observer Scar Assessment Scale (POSAS)
Last Updated
4 years ago

Overview

Brief Summary

The aim of this study is to evaluate the outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who are planning multiport laparoscopic surgery for resection of kidney.

Detailed Description

Study design: This is a prospective, randomized, single center trial. This clinical trial was approved by the Institutional Review Boards. Study process: All patients gave informed written consent after being informed of the details of the study. Subjects were randomized into either the experimental group (specimen removal through posterior vagina fornix incision) or control groups (specimen removal through extended abdominal incision). All participants underwent demographic and history taking, laboratory tests, a gynecologic examination to determine whether specimen removal through vagina is possible. To evaluate cosmesis, patient satisfaction and quality of life VAS (Visual Analogue Scale), SF-12 (Short Form-12) health survey, BIQ (Body Image Questionnaire) and POSAS (the Patient and Observer Scar Assessment Scale) will be sent to the patients 6 months after the surgery.

Registry
clinicaltrials.gov
Start Date
November 29, 2021
End Date
November 29, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients who are accessible with vaginal approach
  • Patients scheduled for laparoscopic resection of kidney for benign or malignant diseases
  • Patients with normal cervical cancer screening tests within the last 3 years except inflammatory findings

Exclusion Criteria

  • Patients without sexual intercourse
  • Patients who are considered unable to remove specimen through vagina due to narrow introitus in gynecological examination
  • Patients who are expected to have severe adhesion due to deep infiltrative endometriosis or previous pelvic surgery history
  • Patients with abnormal cervical cancer screening tests
  • Patients scheduled to perform concomitant hysterectomy

Outcomes

Primary Outcomes

Patient and Observer Scar Assessment Scale (POSAS)

Time Frame: post-op 8 weeks

Cosmetic outcomes of scar assessed by Patient and Observer Scar Assessment Scale (POSAS) 1 week and 8 weeks after surgery. The POSAS is the international validated scar assessment questionnaire that measures quality of the scar from the perspective of both patient and observer. observer scar assessment scale (OSAS): good (1) - bad (10) - vascularization/ pigmentation/ thickness/ relief/ pliability patient scar assessment scale (PSAS): No (1) - Yes (10) * Is the scar painful? * Is the scar itching? * Is the scar color different from the color of your normal skin? * Is the stiffness of the scar different from the color of your normal skin? * Is the thickness of the scar different from the color of your normal skin? * Is the scar more irregular than your normal skin?

Secondary Outcomes

  • Post-op pain assessment(post-op 48hrs)
  • Vaginal wound assessment(post-op 8 weeks)
  • Female Sexual Function Index (FSFI) questionnaire(post-op 5 months)

Similar Trials